Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Non Operating Income (2016 - 2025)

Seres Therapeutics' Other Non Operating Income history spans 10 years, with the latest figure at $2.8 million for Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 112.62% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $21.3 million, up 205.44%, while the annual FY2024 figure was -$14.1 million, 10627.61% down from the prior year.
  • Other Non Operating Income for Q3 2025 was $2.8 million at Seres Therapeutics, down from $4.3 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $7.1 million in Q1 2025 and bottomed at -$22.5 million in Q3 2024.
  • The 5-year median for Other Non Operating Income is -$23000.0 (2022), against an average of -$44789.5.
  • The largest annual shift saw Other Non Operating Income skyrocketed 3127.27% in 2023 before it crashed 2353.95% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$316000.0 in 2021, then soared by 92.72% to -$23000.0 in 2022, then skyrocketed by 1560.87% to $336000.0 in 2023, then surged by 2006.25% to $7.1 million in 2024, then tumbled by 59.86% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Other Non Operating Income are $2.8 million (Q3 2025), $4.3 million (Q2 2025), and $7.1 million (Q1 2025).